
Teleflex (TFX) Stock Forecast & Price Target
Teleflex (TFX) Analyst Ratings
Bulls say
Teleflex has demonstrated a robust potential for growth, with expected sales growth at least around 6% off a nearly $1 billion base, driven by the strategic performance of its interventional business. Key upside drivers include anticipated revenue growth, margin expansion, and further accretive acquisitions, aligning with historical performance trends that supported sustained growth prospects. Additionally, the company’s focus on higher growth products and successful new product launches suggests that Teleflex could achieve organic revenue growth of 4-6%, leading to above-consensus earnings growth in the medium term.
Bears say
Teleflex's stock outlook appears negative due to significantly lower-than-expected revenue growth guidance of 1.0-2.0% for 2025, which falls short of the market's expectation of 4.5%. The company also experienced a revenue shortfall in its 4Q24 results, with GAAP revenue growth projected between -0.4% and 0.7%, indicating challenges in multiple segments, particularly in UroLift and OEM. Furthermore, the announced acquisition of Biotronik's Vascular Intervention business for approximately $820 million and the company’s planned break-up raise concerns about execution risks and potential dilution of earnings per share.
This aggregate rating is based on analysts' research of Teleflex and is not a guaranteed prediction by Public.com or investment advice.
Teleflex (TFX) Analyst Forecast & Price Prediction
Start investing in Teleflex (TFX)
Order type
Buy in
Order amount
Est. shares
0 shares